Influenza A virus vaccine H5N8 - Seqirus

Drug Profile

Influenza A virus vaccine H5N8 - Seqirus

Alternative Names: Inactivated H5N8 vaccine - Seqirus; Monovalent inactivated influenza A vaccine - Seqirus

Latest Information Update: 13 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seqirus
  • Class Influenza A vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus infections

Most Recent Events

  • 05 Jan 2017 National Institute of Allergy and Infectious Diseases plans a phase I trial for Influenza-A virus infections (Prevention) in USA (IM, Injection) (NCT03014310)
  • 01 Aug 2016 Phase-I clinical trials in Influenza-A virus infections (Prevention) in USA (IM) (NCT02624219)
  • 25 Nov 2015 The National Institute of Allergy and Infectious Diseases plans a phase I trial for Influenza A virus infections in USA (NCT02624219)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top